The American Association for Cancer Research has called on Congress "to summarily reject" the Trump administration's 2026 ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi ...

AstraZeneca and Daiichi's Enhertu, followed by THP, has shown pCR rate improvement in the randomised DESTINY-Breast11 Phase ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug ...

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announce that Enhertu hit the main goal in a Phase 3 trial for early-stage ...

Results from phase 2 trials appear to support the use of chemotherapy-free regimens in patients with osimertinib-resistant ...

Treatment with an Enhertu regimen significantly improved pathologic complete responses for patients with high-risk ...

AstraZeneca has announced encouraging high-level results from its DESTINY-Breast11 phase 3 clinical trial, which evaluated ...

Patients on Enhertu followed by a chemotherapy and dual anti-HER2 regimen fared better than those on standard therapy.

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...